Source: European Medicines Agency (EU) Revision Year: 2019 Publisher: Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands
Taltz 80 mg solution for injection in pre-filled syringe.
| Pharmaceutical Form |
|---|
|
Solution for injection in pre-filled syringe (injection). The solution is clear and colourless to slightly yellow. |
Each pre-filled syringe contains 80 mg ixekizumab in 1 ml.
Ixekizumab is a recombinant humanised monoclonal antibody produced in CHO cells.
For the full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
Ixekizumab is an IgG4 monoclonal antibody that binds with high affinity (<3 pM) and specificity to interleukin 17A (both IL-17A and IL-17A/F). Elevated concentrations of IL-17A have been implicated in the pathogenesis of psoriasis by promoting keratinocyte proliferation and activation, as well as in the pathogenesis of psoriatic arthritis. Neutralisation of IL-17A by ixekizumab inhibits these actions. |
| List of Excipients |
|---|
|
Sodium citrate |
1 ml solution in a type I clear glass syringe. Pack sizes of 1, 2, or 3 pre-filled syringes. Not all pack sizes may be marketed.
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands
EU/1/15/1085/004
EU/1/15/1085/005
EU/1/15/1085/006
Date of first authorisation: 25 April 2016
| Drug | Countries | |
|---|---|---|
| TALTZ | Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, Poland, Romania, Singapore, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.